How to Get Peptides Prescribed in the US

If you’ve tried to get a peptide prescribed by asking your usual doctor, you may have hit a wall — not because peptides are illegal, but because the question lands in an unfamiliar corner of US medicine. Getting a legal prescription is rarely about convincing your GP. It’s about understanding who actually prescribes these compounds, what they can and can’t write a script for in 2026, and what a real evaluation looks like.

This page covers the prescriber landscape and the general process. For the step-by-step mechanics of a specific compound, see its dedicated prescription page (such as BPC-157, semaglutide, or ipamorelin). For the regulatory backstory, see the 2026 reclassification explainer.

Why your regular doctor probably won’t prescribe peptides

Technically, any licensed MD, DO, nurse practitioner, or physician assistant in the US can prescribe an off-label or compounded peptide within their scope of practice. In practice, most primary-care physicians decline — and it helps to understand why, because it isn’t obstruction.

Peptide therapy isn’t part of standard medical-school curricula. The evidence base, while growing, is mostly preclinical or early-phase for the wellness peptides, and it isn’t well represented in mainstream clinical guidelines. A conventional GP working from established standards of care has little reason to be comfortable prescribing a compound they were never trained on.

On top of that, several popular peptides sit in a regulatory gray zone. A physician who follows compounding rules closely may simply not want the liability of writing for a substance whose status is unsettled. None of this means the door is closed — it means you usually need to knock on a different one.

Note: “My doctor won’t prescribe it” is not the same as “it’s illegal.” For most of the peptides covered on this site, the issue is provider familiarity and current compounding status, not a blanket legal prohibition.

Which providers actually prescribe peptides

A handful of clinical specialties have built peptide therapy into their practice, and these are where prescriptions usually come from:

Functional and integrative medicine. These practices focus on optimization and root-cause care, and peptides fit naturally into that model. They’re among the most common prescribers.

Regenerative and sports medicine. Clinics oriented around injury recovery, tissue repair, and performance often work with healing-oriented peptides and route prescriptions to compounding pharmacies.

Anti-aging and longevity clinics. Wellness-focused practices that already manage hormone optimization frequently add growth-hormone-axis and longevity peptides.

Hormone and men’s/women’s health clinics. Providers already comfortable with hormone protocols are a natural fit for the growth-hormone-secretagogue and sexual-health peptides.

Telehealth platforms. A growing number of online services connect you with a peptide-knowledgeable licensed provider, run a remote evaluation, and ship pharmacy-prepared medication to your door. Telehealth has become the fastest mainstream route for many people, especially those without a specialty clinic nearby.

The fastest realistic path for most people is to skip primary care entirely and book directly with one of these. A telehealth or in-person specialist will typically evaluate you and, if appropriate, issue a prescription rather than send you on a referral chase.

What you can — and can’t — get a prescription for in 2026

Not every peptide is prescribable in the same way, and this is the single most important thing to understand before you book a consult. US peptides fall into three buckets, and the prescription route differs for each. (The full taxonomy lives on are peptides legal in the US and which peptides are FDA-approved — here’s the version that matters for getting a script.)

Bucket 1 — FDA-approved peptide drugs. The GLP-1s (semaglutide, tirzepatide and their brands), tesamorelin/Egrifta, and bremelanotide/Vyleesi (PT-141) are approved drugs. A prescription here is a normal prescription, filled at a normal pharmacy. These are the easiest to obtain, and telehealth availability for the GLP-1s in particular is broad.

Bucket 2 — compounded peptides. Compounds with no approved branded version — the classic wellness peptides — can be legally prescribed only when a provider writes a script that a 503A compounding pharmacy fills. The prescription itself is straightforward; the limiting factor is whether the pharmacy can currently compound that specific substance (more on this below).

Bucket 3 — research-use-only. “Research peptides” are sold in vials labeled not for human use. There is no prescription involved because there is no patient route here. We cover what this lane is, and its risks, on research peptides explained — it is not a substitute for a prescription.

So before you book, it helps to know which bucket your peptide is in. A consult for an approved drug almost always ends in a fillable prescription. A consult for a compounded peptide depends on current pharmacy access.

What a peptide prescription consult actually involves

Whether in person or by telehealth, a legitimate evaluation follows a recognizable shape. If a service skips most of these steps, treat that as a warning sign rather than convenience.

1. Intake and history. You’ll complete a medical history covering your goal (injury recovery, body composition, energy, libido, and so on), current medications, and relevant conditions.
2. Evaluation, and often labs. Many providers order bloodwork before prescribing — a metabolic panel, and for growth-hormone-axis peptides, markers like IGF-1 interpreted against your age. Labs both screen for contraindications and give a baseline to monitor against.
3. A genuine clinical decision. The provider decides whether a peptide is appropriate for you, and which one. This is the step that makes the prescription real; it isn’t a formality.
4. The prescription and pharmacy step. For an approved drug, the script goes to a standard pharmacy. For a compounded peptide, it routes to a 503A compounding pharmacy that prepares your patient-specific preparation.
5. Follow-up and monitoring. Reputable providers schedule check-ins to track response, adjust the plan, and watch for side effects.

This page deliberately doesn’t include dosing figures or protocols — those are a clinical matter between you and a prescriber, and the right amount is part of the evaluation, not something to settle in advance from a web page.

The mid-2026 compounding gap (why a written script isn’t always fillable)

Here’s the wrinkle that catches people off guard in 2026. In April 2026 the FDA removed a group of wellness peptides — including BPC-157, TB-500, MOTS-c and others — from Category 2, the designation that had effectively barred them from compounding. Headlines framed this as peptides “becoming legal again.”

Removal from Category 2 is not the same as authorization to compound. Those substances now sit in a transitional limbo, pending individual review by the FDA’s Pharmacy Compounding Advisory Committee. The committee meets on July 23–24, 2026 to review the first set, with more to follow, and even a favorable vote is advisory — final compounding access depends on later FDA rulemaking. Realistically, broad pharmacy availability for these compounds may not arrive until late 2026 or 2027.

What this means at the prescription counter: a provider can write you a script for one of these peptides, but many 503A pharmacies are currently declining to compound them while their status is unsettled. So you can hold a valid prescription that no pharmacy will currently fill. For peptides in this group, availability — not finding a willing prescriber — is usually the real bottleneck. Approved drugs (Bucket 1) are unaffected by this; they’re filled normally.

Red flags: when a “prescription” isn’t really one

Because demand is high and the rules are in flux, some operators cut corners. A few signals that a service isn’t offering legitimate prescribed care:

• No real evaluation. A “prescription” issued with no intake, no history, and no provider contact is a paperwork veneer, not medical care.
• No follow-up. Legitimate prescribing includes monitoring. A one-and-done transaction with no check-ins is a flag.
• Selling RUO vials as if prescribed. Any platform openly shipping injectable wellness peptides framed as a prescription, while the compounding status is unsettled, is worth scrutinizing closely.
• Prices far below pharmacy rates. Pricing well under legitimate compounding cost usually points to unregulated, non-pharmacy product.

If you want a structured way to vet a clinic or platform — telehealth versus in person, what to ask, what credentials to check — see how to choose a peptide clinic or telehealth provider.

Telehealth or in person?

Both are legitimate when the provider is licensed and the evaluation is genuine. Telehealth tends to be faster, often cheaper once clinic overhead is stripped out, and accessible from anywhere a provider is licensed to practice. In-person care offers hands-on assessment that some people prefer, particularly for injury- and recovery-oriented goals. The deciding factor is rarely the channel; it’s whether the peptide you want is currently prescribable and fillable, and whether the provider does a real assessment. For most people in 2026, a reputable telehealth specialist is the most direct way to a legal prescription.

Bottom line: Don’t start with your GP. Identify which bucket your peptide is in, choose a provider who actually prescribes peptide therapy, expect a real evaluation with labs, and — for the compounded wellness peptides — check that a pharmacy can currently fill the script before you build your plans around it.

This page reflects US regulatory status current as of the date above. The compounding landscape is moving quickly in 2026 and may change after the July advisory review and any subsequent FDA rulemaking.